Back to Directory
Elsiglutide
Metabolic & Weight ManagementLong-acting GLP-1/Glucagon dual agonist being studied for weight loss and NASH.
Key Benefits
- ✓Weight loss
- ✓Treats NASH
- ✓Dual mechanism
- ✓Weekly dosing
- ✓Metabolic benefits
Dosing Information
Dosage Range
Under investigation
Frequency
Weekly
Typical Duration
Clinical trials
Detailed Protocol
Under clinical development. Weekly subcutaneous injection in trials. Not yet approved.
About Elsiglutide
Elsiglutide is a dual GLP-1/glucagon receptor co-agonist with weekly dosing. Being developed for obesity and NASH. Similar concept to tirzepatide but different receptor profile.
Research Notes
Clinical trials ongoing for obesity and NASH. Part of new class of dual/triple agonist metabolic peptides.
Potential Side Effects
- •GI side effects expected
- •Investigational
Always consult with a healthcare professional before starting any peptide therapy.